ON
🔍
← Back to feed
United StatesBusiness10 days ago

STAT+: Novartis doubles down on molecular glue strategy

The article discusses recent developments in the biotechnology sector, including Novartis' continued investment in its molecular glue strategy, early data on Enliven's leukemia drug, and SonoThera's fundraising for an ultrasound-based gene delivery method. It also mentions rising Medicare drug costs linked to increased use of GLP-1 medications and policy changes.

Seniors’ drug costs rise sharply, Enliven’s leukemia drugs, and more biotech news from The Readout

Anna Yeo/STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox.

Medicare drug spending is climbing faster than expected, driven by surging use of GLP-1 medicines and ongoing fallout from Democrats’ Part D redesign.

Also, Enliven’s leukemia drug has encouraging early data, Novartis is expanding its molecular glue ambitions, and SonoThera raised $125 million to advance an ultrasound-based approach to gene delivery.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter .

Read the full article at STAT News →

1 reports

STAT NewsIndependentCenter10 days ago
STAT+: Novartis doubles down on molecular glue strategy

The article discusses recent developments in the biotechnology sector, including Novartis' continued investment in its molecular glue strategy, early data on Enliven's leukemia drug, and SonoThera's fundraising for an ultrasound-based gene delivery method. It also mentions rising Medicare drug costs linked to increased use of GLP-1 medications and policy changes.

Bias read (Center): The article provides factual updates on biotech advancements without overtly favoring any political stance. It references industry developments and healthcare cost trends but does not present biased language, one-sided sourcing, or editorializing that would indicate a leaning.